The grant was awarded by the Human Frontier Science Program, which promotes international research collaborations.
Epidemiological clues and genotyping data from tens of thousands of individuals with or without Alzheimer's led to an age-specific polygenic risk score.
A pilot program will allow 100 individuals and families with a rare form of epilepsy to receive exome sequencing as part of a larger epilepsy genetics database effort.
The funding builds on more than $1.7 million already awarded to the firm, which is building a diagnostic for characterizing patients in clinical trials.
One team examined single-nucleotide variation, indels, and copy-number variations in ASD, while the other focused on large structural variations.
The deal is expected to strengthen MedDay's existing cerebrospinal fluid-based metabolomics research platform.
Researchers for the InPSYght project are sequencing 10,000 genomes and generating linked-read data for 500 to better understand schizophrenia and bipolar disorder.
The study will involve assaying proteomic markers for dementias including Alzheimer's disease, and understanding genomic markers as part of the normal aging process.
Two studies described de novo gene mutations involved in autism spectrum disorder and other neurodevelopmental conditions, while weeding out unrelated changes.
The companies will work together to identify novel biomarkers of the rare genetic disorder Angelman syndrome.
GeneDx said it will contribute patient data and analytical tools to the UK's Deciphering Developmental Disorders study.
The Cognitive Genomics Consortium researchers said their findings could help understand how the brain works at the molecular level.
The results suggest that targeted treatments used in rare epilepsies might also work in a portion of patients with common forms of the disease.
The partners will work to offer panel-based genetic characterization for a US-based cohort.
The partners will use population genomics to discover and develop novel therapeutics and companion diagnostics for a range of chronic diseases.
Judge Margaret Seymour held a hearing to better understand the facts of the case before deciding whether it should go forward.
The firm, which makes both neurogenetic and oncology diagnostics, also provided updates on its market strategies and menu outlook.
University of Pennsylvania researchers found that patients with autism had a greater mutational burden in essential genes than their unaffected siblings.
The company plans to release its first product in this area, a blood-based proteomic diagnostic for epilepsy, as a laboratory-developed test next year.
The study, which is still ongoing, also provided support for a separate Phase 2/3 trial of a targeted treatment for the neurodevelopmental disorder.
The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.
A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.
Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.
In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.